ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc (ALDX)

5.7599
-0.1301
( -2.21% )
Updated: 10:07:41

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
5.7599
Bid
5.75
Ask
5.78
Volume
38,091
5.72 Day's Range 5.90
1.42 52 Week Range 6.74
Market Cap
Previous Close
5.89
Open
5.90
Last Trade
71
@
5.765
Last Trade Time
10:08:04
Financial Volume
$ 221,352
VWAP
5.8111
Average Volume (3m)
490,747
Shares Outstanding
59,421,551
Dividend Yield
-
PE Ratio
-9.12
Earnings Per Share (EPS)
-0.63
Revenue
-
Net Profit
-37.54M

About Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye dis... Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Aldeyra Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ALDX. The last closing price for Aldeyra Therapeutics was $5.89. Over the last year, Aldeyra Therapeutics shares have traded in a share price range of $ 1.42 to $ 6.74.

Aldeyra Therapeutics currently has 59,421,551 shares outstanding. The market capitalization of Aldeyra Therapeutics is $349.99 million. Aldeyra Therapeutics has a price to earnings ratio (PE ratio) of -9.12.

ALDX Latest News

Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases...

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

New Drug Application Resubmission Anticipated in 2024 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies...

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, August 8, 2024, at 9:00 a.m. (ET) to provide top-line results from the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2701-4.479270315096.036.145.694559425.89402668CS
40.14992.672014260255.616.54765.174694125.91362916CS
122.479975.60670731713.286.54763.14907474.8238678CS
262.829996.58361774742.936.54762.854824524.39359998CS
52-0.3701-6.037520391526.136.741.4211406253.10238463CS
156-2.3801-29.23955773968.1411.971.429223915.02578763CS
260-0.2801-4.637417218546.0415.951.429043696.8078463CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 1.5801
(172.90%)
47.84M
TGLTreasure Global Inc
$ 1.38
(102.85%)
51.23M
NVVENuvve Holding Corporation
$ 6.41
(63.52%)
21.88M
LASELaser Photonics Corporation
$ 15.0883
(44.94%)
2.51M
NCINeo Concept International Group Holdings Ltd
$ 0.9392
(33.22%)
1.25M
ELABElevai Labs Inc
$ 0.112
(-60.00%)
7.14M
ADTXAditxt Inc
$ 0.279799
(-26.87%)
834.55k
ZJYLJin Medical International Ltd
$ 3.119
(-23.55%)
330.99k
FRGTFreight Technologies Inc
$ 0.0872
(-23.37%)
11.04M
PRFXPainReform Ltd
$ 0.591
(-23.36%)
199.73k
XPONExpion360 Inc
$ 0.096901
(14.27%)
244.98M
INTCIntel Corporation
$ 22.404
(2.58%)
53.18M
TGLTreasure Global Inc
$ 1.38
(102.85%)
51.52M
KAVLKaival Brands Innovations Group Inc
$ 1.61
(178.07%)
47.95M
KXINKaixin Holdings
$ 0.0865
(13.82%)
46.71M

ALDX Discussion

View Posts
Investor2014 Investor2014 1 month ago
Sold half at around $5’ish for about 50% profit looking to buy back lower awaiting NDA filing and like decision dates for Reproxalap.
πŸ‘οΈ0
peterus peterus 1 month ago
what your thoughts here for the future?
πŸ‘οΈ0
peterus peterus 1 month ago
hi bro you know a good discord or web for parma and bioΒ΄s
πŸ‘οΈ0
peterus peterus 1 month ago
when offering lol
πŸ‘οΈ0
Investor2014 Investor2014 1 month ago
No one happy here?
πŸ‘οΈ0
Investor2014 Investor2014 2 months ago
Will the dry eye confirmatory P3 trial prove successful this morning? Hard to call, but leaning towards yes.
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
ALDX under $4
πŸ‘οΈ0
jgrabar jgrabar 6 months ago
NOTICE TO LONG-TERM ALDEYRA THERAPEUTICS, INC. (NASDAQ: ALDX) INVESTORS

Grabar Law Office is investigating claims on behalf of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shareholders. The investigation concerns whether certain officers of FMC have breached their fiduciary duties owed to the company.

Current Aldeyra shareholders who have continuously held Aldeyra shares since prior to January 7, 2021 should click here: https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/. You can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to you whatsoever.

Why: A recently filed securities fraud class action complaint alleges that Aldeyra Therapeutics, through certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, it is alleged that the Company made false and misleading statements about or failed to disclose: (i) the ADX-2191 new drug application (β€œNDA”) did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, Aldeyra had overstated ADX-2191's clinical and/or commercial prospects; and (iv) as a result, Aldeyra’s public statements were materially false and misleading at all relevant times.

If you have continuously held Aldeyra shares since prior to January 7, 2021, you are encouraged to visit https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/, contact Joshua H. Grabar at jgrabar @FH-6085.
πŸ‘οΈ0
InvestorPhilia4 InvestorPhilia4 6 months ago
Still progressing here. I think they have been prudent, of late... with the AbbVie option agreement for Reproxalap and other shots on goal without partners. There is certainly upside with continued clinical success. Any updated views on Aldeyra?
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0
InvestorPhilia4 InvestorPhilia4 11 months ago
I added 3,500 shares on 10/16 as well below $1.80. I wish I leaned in more. I am a holder and still see long-term upside from here.
πŸ‘οΈ0
Invest-in-America Invest-in-America 11 months ago
ALDX: Just crossed the (dangerous) 1.5-Hrs-Into-The-Open-Rubicon, and movin' UP from there!! (Not easy to do for ANY stock.)
πŸ‘οΈ0
green maschine green maschine 11 months ago
Nice grab. It's good to be the early bird. I knew nothing about the company, just saw the news.
πŸ‘οΈ0
Invest-in-America Invest-in-America 11 months ago
Me too, Dude. (And this Firm has worked on this drug for a long time; and that ain't NO 'small-potatoes' Company that just partnered with them either.)

πŸ‘οΈ0
green maschine green maschine 11 months ago
Yep. I snatched up some of this pre-market.
πŸ‘οΈ0
Invest-in-America Invest-in-America 11 months ago
ALDX: Could have a good day here; 'Dry Eye' syndrome afflicts MILLIONS worldwide!
πŸ‘οΈ0
Investor2014 Investor2014 11 months ago
I bought to average down today, it seems a sensible move.
πŸ‘οΈ0
InvestorPhilia4 InvestorPhilia4 11 months ago
With the pending readouts and relatively short trials that may provide additional support, I agree.

Also, the company has some breathing room with > $2 per share in cash after all liabilities as of 6/30 and only burning ~ $0.20 per share quarterly.

The current sub $2 share price looks attractive to me.
πŸ‘οΈ0
Investor2014 Investor2014 11 months ago
Ouch indeed, but it isn’t over for dry eye and we are expecting one other different P3 indication readout this year.
πŸ‘οΈ0
InvestorPhilia4 InvestorPhilia4 11 months ago
Ouch
πŸ‘οΈ0
Investor2014 Investor2014 1 year ago
A not so great day yesterday for $ALDX.

Small potential indication costing the 25% run up we have in expectation of H2 events.

It isn’t over for ADX-2191 yet though…
πŸ‘οΈ0
InvestorPhilia4 InvestorPhilia4 2 years ago
I have been invested here (smaller position than in AVXL) also. Binary/inflection points appear to be ahead mid-2023. We appear to have several shots on goal.
πŸ‘οΈ0
Investor2014 Investor2014 2 years ago
Yet another great day for aldeyra.

No one invested here?
πŸ‘οΈ0
Investor2014 Investor2014 2 years ago
Another great day for Aldeyra. In due course probably pay handsomely.
πŸ‘οΈ0
Investor2014 Investor2014 2 years ago
Good day for Aldeyra!
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
That’s biotech.
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
what I meant was the time line

mid 2022

πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
Agree and believe that is what I just said.
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
yeah but heres the kicker

ALDX
Primary Endpoint of TRANQUILITY-2 Trial Modified to be Met if Either Ocular Redness or Schirmer Test Achieved; Target Enrollment Increased from 300 to up to 400 Patients; Top-Line Results Expected Mid-2022
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
So TRANQUILITY-2 endpoints to be changed to meet either Redness or Schirmer for potential approval.

Could be fine not least given that secondary p-value.

Still hope!
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
ALDX NEWS https://www.streetinsider.com/Business+Wire/Aldeyra+Therapeutics+Announces+Top-Line+Results+from+the+Phase+3+TRANQUILITY+Trial+in+Dry+Eye+Disease/19374659.html
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
Yeah not good.
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
NEWS HALT ))) 12/20/2021 16:00:34 ALDX Aldeyra Therapeutics Cmn Stk NASDAQ
T1
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
Looks like the market finally clicked that ocular redness is the primary endpoint over the conventional Schirmer’s test as agreed by the FDA trial protocol.

πŸ‘οΈ0
Rayn_Makr Rayn_Makr 3 years ago
ADX-1612 and ADX-1615, Chaperome Inhibitors

Last summer I dove into the mechanism of action for ADX-1612 and spent a fair amount of time looking at HSP90 on PubMed. It is a widely recognized target. It will be interesting to see how the numerous assets at ALDX are managed. It's challenging to put a market cap and time to reach that value but they have great potential, no doubt. Current market conditions will probably make for a wild ride. Good Luck!

https://pubmed.ncbi.nlm.nih.gov/?term=hsp90+inhibitor
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
I agree, ALDX has great potential.
πŸ‘οΈ0
Rayn_Makr Rayn_Makr 3 years ago
RASP-INHIBITION IN SYSTEMIC DISEASES

ADX-629 became a topic in the recent conference call so I did a revisit of that therapeutic. Glad I did since ADX-629 offers an impressive opportunity to further RASP inhibition. Several nuggets to pass along from a quick review of ADX-629:

The clinical trial NCT04847544 for Treatment of COVID-19 was initiated in April. It is recruiting N=30 and estimated completion this year.

https://clinicaltrials.gov/ct2/show/NCT04847544?term=aldeyra&recrs=abdf&draw=2&rank=1

Secondly, the phase 1 results showed target engagement "Also Improved Lipid Profiles". Lipid therapeutics have a large market, i.e., cardiovascular disease. Look at slide #17.

https://ir.aldeyra.com/static-files/33742ce3-ebdc-4569-9f65-b5b7bd8c73eb

The asthma trial is also on the trial list.

https://clinicaltrials.gov/ct2/results?term=aldeyra&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt=&Search=Apply%5D

Six ongoing clinical trials explains the recent raise in capital and great timing on that. Kudos to management!
πŸ‘οΈ0
Rayn_Makr Rayn_Makr 3 years ago
Perceptive Advisors SEC form 4
3 May 2021 shows 1,200,000 shares bought at $12.50 = $15,000,000
They now have a total of 9.9 million shares which at $12.50 = $123,750,000. They have been adding since July 2020. Safe to say they have a positive outlook, eh?
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
It will stay above the $12.50 offer price just like last time especially given the great P3 trial readout.
πŸ‘οΈ0
make it happen make it happen 3 years ago
I wouldn't touch this personally with a ten foot stick for a while not bashing but that's a heck of a lot of dilution coming out. 125 million dollars and able to add a lot more.
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
Bought in again @$12.89.
πŸ‘οΈ0
make it happen make it happen 3 years ago
Huge $125,000,000 offering & can add another $18,750,000 million
πŸ‘οΈ0
make it happen make it happen 3 years ago
Most def
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
Sold today avg $15.07. Figured they’d needmore funding and the price would dip waiting for a NDA filing and next P3 readout in H2.

Plenty time to buy back in cheaper, which should be a nice long term hold.
πŸ‘οΈ0
ClayTrader ClayTrader 3 years ago
* * $ALDX Video Chart 04-27-2021 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
make it happen make it happen 3 years ago
Good volume. When it slows it'll fade hard imho Wish could get locates some where. 4x highest volume day ever
πŸ‘οΈ0
altruism altruism 3 years ago
Billion dollars traded today so far
πŸ‘οΈ0
make it happen make it happen 3 years ago
Yes, usually have something going on or at least some kind revenues from something. Not just spending money.
πŸ‘οΈ0
altruism altruism 3 years ago
Looking GOOD
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
You seem surprised. Ever invested in pre-revenue biotechs?
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock